PI3K inhib 
Welcome,         Profile    Billing    Logout  
 67 Companies  59 Products   59 Products   344 Diseases   343 Trials   12261 News 


«12...157158159160161162163164165166167...229230»
  • ||||||||||  Journal:  Lactobacillus reuteri extracts promoted wound healing via PI3K/AKT/β-catenin/TGFβ1 pathway. (Pubmed Central) -  Jul 18, 2020   
    These data showed that Lactobacillus reuteri extracts could activate the potentials of GMSCs, thus promote wound healing. Our discovery provided the insight of the underlying mechanism activating functions of MSCs and identified Lactobacillus reuteri extracts as a potential therapeutic strategy for accelerating oral wound and potential application in the future dental clinic.
  • ||||||||||  R-(-)-gossypol (AT 101) / Ascentage Pharma, Herceptin (trastuzumab) / Roche
    Journal, Combination therapy:  Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells. (Pubmed Central) -  Jul 18, 2020   
    Combination treatment induced cytotoxicity via inhibiting PI3K/AKT but not the MAPK/ERK pathway. The trastuzumab/AT-101 combination may be a good candidate for patients with trastuzumab-resistant Her2-positive breast cancer and inhibition of the PI3K/AKT pathway may be one of the underlying mechanisms.
  • ||||||||||  Journal:  Metastasis suppressor protein 1 regulated by PTEN suppresses invasion, migration, and EMT of gastric carcinoma by inactivating PI3K/AKT signaling. (Pubmed Central) -  Jul 16, 2020   
    Our mechanistic investigations revealed that MTSS1 was positively regulated by the phosphatase and tensin homolog (PTEN), and it functioned as a tumor suppressor, possibly by inactivating the phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma viral oncogene (AKT) pathway in GC cells. Collectively, our data provide insight into an important role for MTSS1 in suppressing tumor cell invasion, migration and EMT, which indicates that MTSS1 may act as a prospective prognostic biological marker and a promising therapeutic target for GC.
  • ||||||||||  Journal:  Human B Cells Engage the NCK/PI3K/RAC1 Axis to Internalize Large Particles via the IgM-BCR. (Pubmed Central) -  Jul 16, 2020   
    Furthermore, we demonstrate that the IgM-BCR/NCK signaling event facilitates RAC1 activation to promote actin cytoskeleton remodeling necessary for particle engulfment. Thus, we establish NCK/PI3K/RAC1 as an attractive IgM-BCR signaling axis for biological intervention to prevent undesired antibody responses to large particles.
  • ||||||||||  quercetin (LY294002) / Eli Lilly
    Journal:  FAM3A protects chondrocytes against interleukin-1β-induced apoptosis through regulating PI3K/Akt/mTOR pathway. (Pubmed Central) -  Jul 16, 2020   
    Moreover, mechanistically, FAM3A activated PI3K/Akt/mTOR pathway in IL-1β-treated chondrocytes, and blockade of PI3K/Akt/mTOR pathway with specific inhibitors, wortmannin and LY294002, diminished FAM3A effect on IL-1β-induced chondrocyte apoptosis, hence demonstrating that FAM3A attenuates IL-1β-induced chondrocyte apoptosis through activating the pro-survival PI3K/Akt/mTOR pathway. In conclusion, our study may identify FAM3A as a potential regulator of chondrocyte apoptosis involved in OA pathogenesis.
  • ||||||||||  omipalisib (GSK2126458) / GSK
    Preclinical, Journal:  PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices. (Pubmed Central) -  Jul 16, 2020   
    Omipalisib has antifibrotic properties in ex vivo mouse and human liver PCTS, but higher concentrations showed toxicity in jejunum PCTS. While the PI3K/mTOR pathway appears to be a promising target for the treatment of liver fibrosis, PCTS revealed likely side effects in the intestine at higher doses.
  • ||||||||||  Journal:  PI3Kα in cardioprotection: Cytoskeleton, late Na current, and mechanism of arrhythmias. (Pubmed Central) -  Jul 16, 2020   
    Heightened activity of PI3Kα in many types of cancer made it a prime oncology drug target, but also raises concerns of possible adverse effects on the heart. Indeed, recent advances in preclinical models demonstrate an important role of PI3Kα in the control of cytoskeletal integrity, Na channel activity, cardioprotection, and prevention of arrhythmias.
  • ||||||||||  Journal:  Is Phosphatidylinositol 3- kinase (PI3K) a Villain in Cystic Fibrosis? (Pubmed Central) -  Jul 16, 2020   
    Together, these results reveal an important role of miR-92a in LPS-induced endothelial barrier dysfunction, and suggest that miR-92a may have potential as a prognostic indicator and a future target for the treatment of acute lung injury (ALI)/ARDS. No abstract available
  • ||||||||||  quercetin (LY294002) / Eli Lilly, dactolisib (RTB101) / resTORbio
    [VIRTUAL] PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma (Pre-congress content) -  Jul 15, 2020 - Abstract #ERS2020ERS_2164;    
    The ability of compounds including PI3K inhibitors (BEZ235 and LY294002) to ameliorate GC insensitivity in severe asthma was evaluated. This study demonstrates that PI3K inhibitors ameliorate GC insensitivity in severe asthma by restoring HDAC2 activity and inhibiting the phosphorylation of nuclear signaling transcription factors.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] What is Fitness in the Era of Targeted Agents? () -  Jul 14, 2020 - Abstract #SOHO2020SOHO_186;    
    The venetoclax-obinutuzumab combination has been specifically addressed to patients with coexisting conditions; patients were enrolled in the study if they had a total CIRS score > 6 or a CrCl < 70 mL/min...New target agents have changed the CLL standard of care; prospective studies evaluating patients outside clinical trials are needed to better define the prognostic value of CIRS and to determine the optimal approach towards those who have significant comorbidities. Another issue that should be considered when analyzing fitness and tolerability for targeted drugs is polypharmacy and drug interactions; none of the studies so far have analyzed their impact on treatment outcome.
  • ||||||||||  Journal:  Yak OXGR1 promotes fibroblast proliferation via the PI3K/AKT pathways. (Pubmed Central) -  Jul 10, 2020   
    These results illustrated that changes of OXGR1 expression can trigger the fibroblasts proliferation via PI3K/AKT signaling pathway, which indicating that OXGR1 is a novel regulator for cell proliferation and differentiation. Furthermore, these results provide evidence supporting the functional role of GPCRs-PI3K-AKT1 and OXGR1 in cell proliferation.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca, dactolisib (RTB101) / resTORbio
    Journal, PARP Biomarker:  BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. (Pubmed Central) -  Jul 10, 2020   
    PI3K inhibition induces substantial DNA damage and makes cells more dependent on PARP activity in the context of BRIT1 deficiency, thus, BRIT1 depletion facilitates enhancing synthetic lethality of PARP inhibitors and PI3K inhibitors in HCC. This study provides a new mechanistic foundation for significantly expanding the application of PARPi in HCC therapy.
  • ||||||||||  Journal:  PI3Kβ is selectively required for growth factor-stimulated macropinocytosis. (Pubmed Central) -  Jul 9, 2020   
    PI3Kβ is also required for the elevated levels of constitutive macropinocytosis found in tumor cells that are defective for the PTEN tumor suppressor. Our data shed new light on PI3K signaling during macropinocytosis, and suggest new therapeutic uses for pharmacological inhibitors of PI3Kβ.